• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.

作者信息

Xu Jiasheng, Jiang Qidi, Xu Hua, Liu Anwen, Huang Long

机构信息

Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China; Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, P. R. China.

Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China; Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, P. R. China.

出版信息

J Thorac Oncol. 2020 Apr;15(4):e49-e51. doi: 10.1016/j.jtho.2019.11.026.

DOI:10.1016/j.jtho.2019.11.026
PMID:32216945
Abstract
摘要

相似文献

1
Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.两名患有非小细胞肺癌且其表皮生长因子受体基因存在新型重复突变（p.I740_K745dupIPVAIK）的患者及其对奥希替尼的反应。
J Thorac Oncol. 2020 Apr;15(4):e49-e51. doi: 10.1016/j.jtho.2019.11.026.
2
Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation.携带EGFR V843I种系突变的非小细胞肺癌患者对奥希替尼的反应
Lung Cancer. 2020 Dec;150:247-248. doi: 10.1016/j.lungcan.2020.09.019. Epub 2020 Sep 28.
3
Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.奥希替尼用于治疗EGFR突变型非小细胞肺癌的软脑膜疾病
J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.
4
Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.在中国非小细胞肺癌患者中鉴定出一种新型的对奥希替尼敏感的突变，即EGFR H773L。
J Thorac Oncol. 2020 Mar;15(3):e46-e48. doi: 10.1016/j.jtho.2019.11.018.
5
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.奥希替尼引领改善伴有软脑膜转移的EGFR突变型非小细胞肺癌的治疗结果之路。
J Thorac Oncol. 2021 Feb;16(2):e12-e14. doi: 10.1016/j.jtho.2020.10.016.
6
A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.对致编辑信的回应：奥希替尼引领改善伴有软脑膜转移的EGFR突变型非小细胞肺癌的治疗结果之路。
J Thorac Oncol. 2021 Feb;16(2):e14. doi: 10.1016/j.jtho.2020.12.009.
7
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.在辅助治疗中，奥希替尼目前不应被视为EGFR突变型非小细胞肺癌的标准治疗方案。
J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.
8
Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.克服非小细胞肺癌对奥希替尼的耐药性：希望、疑虑与中间地带。
Cancer. 2020 Jun 1;126(11):2594-2596. doi: 10.1002/cncr.32810. Epub 2020 Mar 10.
9
Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.表皮生长因子受体（EGFR）和转染期间重排（RET）联合抑制用于治疗表皮生长因子受体突变的非小细胞肺癌（NSCLC）对奥希替尼的获得性耐药
Ann Pharmacother. 2022 Apr;56(4):503-504. doi: 10.1177/10600280211036909. Epub 2021 Aug 3.
10
Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the T790M Mutation After Failure of Initial EGFR-TKI Treatment.奥希替尼在初始EGFR-TKI治疗失败后携带T790M突变的老年非小细胞肺癌患者中的疗效和安全性数据。
Anticancer Res. 2018 Sep;38(9):5231-5237. doi: 10.21873/anticanres.12847.

引用本文的文献

1
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions.表皮生长因子受体（EGFR）第19外显子插入的非小细胞肺癌患者的分子特征及对EGFR酪氨酸激酶抑制剂的反应
BMC Med. 2025 Apr 29;23(1):249. doi: 10.1186/s12916-025-04075-1.
2
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.EGFR 外显子 19 插入 EGFR-K745_E746insIPVAIK 和其他罕见的 XPVAIK 氨基酸插入：所有批准的 EGFR 激酶抑制剂的有利治疗窗口的临床前和临床特征。
Lung Cancer. 2023 Jul;181:107250. doi: 10.1016/j.lungcan.2023.107250. Epub 2023 May 13.
3
Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review.以奥希替尼为中心治疗罕见表皮生长因子受体突变型非小细胞肺癌——一篇综述
Front Oncol. 2022 Apr 14;12:834585. doi: 10.3389/fonc.2022.834585. eCollection 2022.
4
Efficacy of EGFR-TKI sequential therapy in patients with exon 19 insertion-positive non-small-cell lung cancer: A case report.表皮生长因子受体酪氨酸激酶抑制剂序贯疗法治疗19外显子插入阳性非小细胞肺癌患者的疗效：一例报告
World J Clin Cases. 2022 Feb 26;10(6):1883-1888. doi: 10.12998/wjcc.v10.i6.1883.
5
A Nationwide Study on the Impact of Routine Testing for Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on Mutation Subclasses.一项关于晚期非小细胞肺癌（NSCLC）突变常规检测影响的全国性研究揭示了基于突变亚类的不同生存模式。
Cancers (Basel). 2021 Jul 20;13(14):3641. doi: 10.3390/cancers13143641.